Earlier this summer, pharmaceutical company Eli Lilly announced their results from phase III trials of their drug solanezumab.  Yesterday, they announced that their findings have been independently confirmed by ADCS.

The results are not what Eli Lilly had hoped to announce because the drug did not achieve the goals Eli Lilly set for the tests.  Solanezumab, a monoclonal antibody, was targeted to slow the rate of neurologic decline as a result of Alzheimer's Disease by removing the build up of beta amyloid.   However, there was a slowing of the cognitive decline noted in trial participants who had mild Alzheimer's.  In other words, solanezumab may actually have a moderate clinical benefit.

Additional Information:
Mixed Phase III Results for Solanezumab in Alzheimer's Disease


Popular Posts